Beijer Alma meddelar att man ingått avtal om att avyttra dotterbolaget Habia Cable till tyska HEW-KA...
Redeye ser positivt på nyheten att FDA accepterat Eisais registreringsansökan för Lecanemab under de...
Both CEPS and NAV trimmed by ~1-3% Relatively good funding conditions and low LTV Trading at ~40% ...
Q2 report due on 15 July We expect sales of SEK 444m and EBITA of 66m We lower our ’23-24e EBITA by ...
Q2 report due on July 19 We expect sales of SEK 190m and adj.
Redeye comments on the outcome of Scandion’s rights issue, and we resume our coverage.
Redeye adjusts its fair value range following the announced rights issue (assuming full subscription...
Q2 report due on Tuesday, 12 July Proved earnings resiliency in Q1, more of the same in Q2 10x ’22e ...
Net operating income -3% vs. ABGSCe Occupancy rate intact at ~92% ~12x LTM P/IFPM vs 5y average of 1...
Defensive rights issue below NAV… …but strengthens the balance sheet Two largest owners increase the...
Redeye is encouraged to learn that Orexo has initiated the clinical development of Orexo’s OX640 pro...
Redeye leaves a short comment following Initiator Pharma’s announcement earlier today of a minor dir...
Qlosr är en helhetsleverantör av IT-lösningar som säljs via prenumeration vari Bolaget adresserar SM...
Redeye leaves a short comment on today’s press release from Xbrane stating that the company intends ...
As sporting activity tends to soften throughout the second quarter with major leagues finishing thei...
Redeye retains its positive view of Formpipe following its deliveries deal with Malmö Stad.
Redeye retains its positive view on Transtema following the small yet interesting acquisitions of EV...
Redeye is encouraged by Enviro’s latest regulatory progress – attaining an environmental permit for ...
Redeye comments on Spago Nanomedical announcing the outcome of its rights issue, sporting a subscrip...
Yesterday evening, Nitro Games announced that it received a follow-up B2B order from an existing US-...
